Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00517985 · ClinicalTrials.gov registry record · Phase 4
Duloxetine for Perimenopausal Depression
A Phase 4 study of Major Depressive Disorder, sponsored by University of Arizona.
- Completed
- Registry status
- Phase 4
- Development phase
- 7
- Enrollment target
- 1
- Study location
NCT00517985: Completed Phase 4 study of Major Depressive Disorder, sponsored by University of Arizona.
NCT00517985 is a Phase 4 study of Major Depressive Disorder that has completed, run by University of Arizona. The registered enrollment target is 7 participants, below the 377-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00517985, a Phase 4 study of Major Depressive Disorder, has completed, sponsored by University of Arizona.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 7 participants
- Enrollment target
- 1
- Study location
Study Summary
Recently, antidepressants have been explored as a class of medications to treat major depression in the context of perimenopause, as well as the somatic symptoms of perimenopause (such as hot flashes). Duloxetine (Cymbalta) is one of the newer antidepressants approved for the treatment of Major Depressive Disorder (MDD). Therefore, the current study is designed to assess the efficacy of duloxetine in a sample of women who are perimenopausal and meet criteria for MDD. We will assess impact on MDD and perimenopausal symptoms.
Conditions Studied
Interventions
- DRUG Duloxetine
Study Locations (1)
Arizona
- Women's Mental Health Program; University of Arizona; Department of Psychiatry - Tucson
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2007-02 |
| Est. Completion | 2008-06 |
| Phase | Phase 4 |
What the finished NCT00517985 record still lists
NCT00517985 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 7 participants, a relatively small participant target, below the 377-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Major Depressive Disorder appearing as the primary indexed condition, and to 1 intervention - of which Duloxetine is the first listed.
NCT00517985 reports a single indexed study location in Arizona.
Frequently Asked Questions
What is clinical trial NCT00517985 about?
NCT00517985 is a clinical study titled "Duloxetine for Perimenopausal Depression". Recently, antidepressants have been explored as a class of medications to treat major depression in the context of perimenopause, as well as the somatic symptoms of perimenopause (such as hot flashes). Duloxetine (Cymbalta) is one of the newer antidepressants approved for the treatment of Major Depr...
What is the current status of trial NCT00517985?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 7 participants. The study started on 2007-02. Estimated completion is 2008-06.
What conditions does trial NCT00517985 study?
This clinical trial studies the following conditions: Major Depressive Disorder.
What interventions are being tested in trial NCT00517985?
The interventions under investigation include: Duloxetine (DRUG).
Who is sponsoring clinical trial NCT00517985?
This trial is sponsored by University of Arizona, which has 349 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00517985 being conducted?
This trial has 1 study location across Arizona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Major Depressive Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00517985's enrollment target sits among peer trials
7 281st of 282 higher than 2 of 282 other Major Depressive Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Major Depressive Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor
RECRUITING · Phase 4
-
A Study to Evaluate the Efficacy of AXS-05 Compared to Bupropion in Preventing the Relapse of Depressive Symptoms
RECRUITING · Phase 4
-
Establishing Multimodal Brain Biomarkers for Treatment Selection in Depression
RECRUITING · Phase 4
-
Neural Circuit Effects of Ketamine in Depression
RECRUITING · Phase 4
-
Aβ Dynamics in LLMD
RECRUITING · Phase 4
-
Long-Term Maintenance With Ketamine and Esketamine for Reduction of Suicide in High-Risk Patients With Depression
RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia